<info type="SequenceVariant">polymorphisms</info> in the <info type="GeneOrGeneProduct">carbonyl reductase 3 gene CBR3</info> and the <info type="GeneOrGeneProduct">NAD(P)H:quinone oxidoreductase 1 gene NQO1</info> in patients who developed <info type="DiseaseOrPhenotypicFeature">anthracycline-related congestive heart failure</info> after <info type="DiseaseOrPhenotypicFeature">childhood cancer</info>.

BACKGROUND: Exposure to <info type="ChemicalEntity">anthracyclines</info> as part of <info type="DiseaseOrPhenotypicFeature">cancer therapy</info> has been associated with the development of <info type="DiseaseOrPhenotypicFeature">congestive heart failure</info> (<info type="DiseaseOrPhenotypicFeature">CHF</info>). The potential role of <info type="GeneOrGeneProduct">genetic risk factors</info> in <info type="DiseaseOrPhenotypicFeature">anthracycline-related CHF</info> remains to be defined. Thus, in this study, the authors examined whether common <info type="SequenceVariant">polymorphisms</info> in candidate <info type="GeneOrGeneProduct">genes</info> involved in the pharmacodynamics of <info type="ChemicalEntity">anthracyclines</info> (in particular, the <info type="GeneOrGeneProduct">nicotinamide adenine dinucleotide phosphate:quinone oxidoreductase 1 gene NQO1</info> and the <info type="GeneOrGeneProduct">carbonyl reductase 3 gene CBR3</info>) had an impact on the risk of <info type="DiseaseOrPhenotypicFeature">anthracycline-related CHF</info>. METHODS: A nested case-control study was conducted within a cohort of <info type="OrganismTaxon">1979 patients</info> enrolled in the <info type="DiseaseOrPhenotypicFeature">Childhood Cancer Survivor Study</info> who received treatment with <info type="ChemicalEntity">anthracyclines</info> and had available <info type="GeneOrGeneProduct">DNA</info>. Thirty patients with <info type="DiseaseOrPhenotypicFeature">CHF</info> (cases) and <info type="OrganismTaxon">115 matched controls</info> were genotyped for <info type="SequenceVariant">polymorphisms</info> in <info type="GeneOrGeneProduct">NQO1</info> (<info type="SequenceVariant">NQO1*2</info>) and <info type="GeneOrGeneProduct">CBR3</info> (the <info type="GeneOrGeneProduct">CBR3</info> <info type="SequenceVariant">valine [V] to methionine [M] substitution at position 244 [V244M]</info>). Enzyme activity assays with recombinant <info type="GeneOrGeneProduct">CBR3 isoforms</info> (<info type="GeneOrGeneProduct">CBR3 V244</info> and <info type="GeneOrGeneProduct">CBR3 M244</info>) and the <info type="ChemicalEntity">anthracycline substrate doxorubicin</info> were used to investigate the functional impact of the <info type="SequenceVariant">CBR3 V244M polymorphism</info>. RESULTS: Multivariate analyses adjusted for <info type="GeneOrGeneProduct">sex</info> and <info type="DiseaseOrPhenotypicFeature">primary disease recurrence</info> were used to test for associations between the candidate <info type="SequenceVariant">genetic polymorphisms</info> (<info type="SequenceVariant">NQO1*2</info> and <info type="SequenceVariant">CBR3 V244M</info>) and the risk of <info type="DiseaseOrPhenotypicFeature">CHF</info>. Analyses indicated no association between the <info type="SequenceVariant">NQO1*2 polymorphism</info> and the risk of <info type="DiseaseOrPhenotypicFeature">anthracycline-related CHF</info> (odds ratio [OR], 1.04; P=.97). There was a trend toward an association between the <info type="SequenceVariant">CBR3 V244M polymorphism</info> and the risk of <info type="DiseaseOrPhenotypicFeature">CHF</info> (OR, 8.16; P=.056 for G/G vs A/A; OR, 5.44; P=.092 for G/A vs A/A). In line, recombinant <info type="GeneOrGeneProduct">CBR3 V244</info> (<info type="GeneOrGeneProduct">G allele</info>) synthesized <info type="ChemicalEntity">2.6-fold more cardiotoxic doxorubicinol</info> per unit of time than <info type="GeneOrGeneProduct">CBR3 M244</info> (<info type="GeneOrGeneProduct">A allele</info>; <info type="GeneOrGeneProduct">CBR3 V244</info> [8.26+/-3.57 <info type="ChemicalEntity">nmol/hour.mg</info>] vs <info type="GeneOrGeneProduct">CBR3 M244</info> [3.22+/-0.67 <info type="ChemicalEntity">nmol/hour.mg</info>]; P=.01). CONCLUSIONS: The functional <info type="SequenceVariant">CBR3 V244M polymorphism</info> may have an impact on the risk of <info type="DiseaseOrPhenotypicFeature">anthracycline-related CHF</info> among <info type="DiseaseOrPhenotypicFeature">childhood cancer survivors</info> by modulating the intracardiac formation of cardiotoxic <info type="ChemicalEntity">anthracycline alcohol metabolites</info>. Larger confirmatory case-control studies are warranted.